Low-Dose Naltrexone for Pruritus in Systemic Sclerosis
نویسندگان
چکیده
Pruritus is a common symptom in systemic sclerosis (SSc), an autoimmune disease which causes fibrosis and vasculopathy in skin, lung, and gastrointestinal tract (GIT). Unfortunately, pruritus has limited treatment options in this disease. Pilot trials of low-dose naltrexone hydrochloride (LDN) for pruritus, pain, and quality of life (QOL) in other GIT diseases have been successful. In this case series we report three patients that had significant improvement in pruritus and total GIT symptoms as measured by the 10-point faces scale and the University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 (UCLA SCTC GIT 2.0) questionnaire. This small case series suggests LDN may be an effective, highly tolerable, and inexpensive treatment for pruritus and GIT symptoms in SSc.
منابع مشابه
Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis
INTRODUCTION A retrospective study was conducted on patients at Penn State Hershey Medical Center diagnosed with relapsing-remitting multiple sclerosis between 2006 and 2015. METHODOLOGY Laboratory and clinical data collected over this 10-year period were reviewed. Two cohorts of patients were established based on their relapsing-remitting multiple sclerosis therapy at the time of their first...
متن کاملPharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials.
BACKGROUND AND OBJECTIVE Numerous drugs have been used to prevent or to treat opioid-induced pruritus in the surgical setting. Their relative efficacy is not well understood. METHODS The methods employed involved the systematic search (MEDLINE, EMBASE, Cochrane library, bibliographies, without language restriction, up to June 2000) for full reports of randomized comparisons of any interventio...
متن کاملLow-dose naltrexone for treatment of multiple sclerosis: clinical trials are needed.
TO THE EDITOR: Multiple sclerosis (MS) is generally thought to be an autoimmune disease. Current estimates suggest that there are up to 400 000 patients diagnosed with MS in the US.1 In all forms of MS, both inflammatory and neurodegenerative processes affect the disease. After receiving several questions regarding the use of low-dose naltrexone for MS, I performed a search of MEDLINE (1966-May...
متن کاملA pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
A sixth month phase II multicenter-pilot trial with a low dose of the opiate antagonist Naltrexone (LDN) has been carried out in 40 patients with primary progressive multiple sclerosis (PPMS). The primary end points were safety and tolerability. Secondary outcomes were efficacy on spasticity, pain, fatigue, depression, and quality of life. Clinical and biochemical evaluations were serially perf...
متن کاملTreatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS
Naltrexone is an opiate m-receptor antagonist approved for treatment of alcohol dependency at a recommended dose of 50 mg/day. The mechanism of action is proposed to be mediated by a normalization of endogenous endorphin levels. Despite few and inconclusive studies (casuistic or open-label), a naltrexone dose of 3–5 mg/day (low-dose naltrexone, LDN) has been suggested to ameliorate a wide range...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
دوره 2011 شماره
صفحات -
تاریخ انتشار 2011